Pfizer wins FDA nod for Prevnar 20 pneumonia vaccine in children

• Pfizer (NYSE:PFE) announced Thursday that the FDA approved its pneumonia vaccine Prevnar 20 for use in infants and children six weeks through 17 years of age for the prevention of invasive pneumococcal disease (IPD).
• The agency has also cleared Prevnar 20 for otitis media (middle ear infection) in infants six weeks through five years of age.
• Compared to the company’s PREVNAR 13 vaccine, Prevnar 20 contains seven more serotypes of Streptococcus pneumoniae, helping to protect against 20 serotypes of pneumococcal bacteria linked to pediatric pneumococcal cases.
• The Center for Disease Control and Prevention (CDC) which decides on the nationwide rollout of vaccines, is expected to act as soon as possible following the FDA approval, Pfizer (PFE) said, adding the agency has scheduled an AdCom meeting in this regard on June 21-22, 2023.

More on Prevnar 20

• FDA approves Pfizer's Prevnar 20 for adults age 18 years or older
• CDC advisors recommend Pfizer Prevnar 20 pneumonia vaccine in adults